Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 6 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $394.5M in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysLast 90 days, $5.23M in total
- 6
- Insider sellsLast 90 days, $1.27M in total
- 7
- 13F holdersQ2 2026, +32 vs. previous quarter
- 72
- 13F valueReported value at the end of Q2 2026
- $394.5M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding ARTV, Q2 2026
1 superinvestor reports holding Artiva Biotherapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Artiva Biotherapeutics, Inc.'s share of the portfolio
- Shares
- 2,604,166
- Value
- $25.3M
Latest insider trades
Open-market purchases and sales by Artiva Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)4:02 PM ET | Sep 8 | 1 day | Aslan FredChief Executive Officer | SSale | −23.4K | $10.92 | −$255.7K | −1.6%1.45M after | 10b5-1 |
| Sep 4, 2026 (view filing)4:04 PM ET | Sep 3 | 1 day | Horan ChristopherChief Tech Operations Officer | SSale | −10.4K | $11.16 | −$115.6K | −3.5%283.1K after | |
| Sep 4, 2026 (view filing)4:03 PM ET | Sep 3 | 1 day | Bush JenniferCOO, CLO, Compliance Officer | SSale | −8.39K | $11.16 | −$93.6K | −2.5%329.5K after | |
| Sep 4, 2026 (view filing)4:03 PM ET | Sep 3 | 1 day | Banerjee SubhashisChief Medical Officer | SSale | −1.10K | $11.16 | −$12.3K | −0.8%140.9K after | |
| Sep 4, 2026 (view filing)4:02 PM ET | Sep 3 | 1 day | Aslan FredChief Executive Officer | SSale | −61.9K | $11.16 | −$690.4K | −4.0%1.47M after | |
| Aug 31, 2026 (view filing)7:06 PM ET | Aug 27 | 4 days | Banerjee SubhashisChief Medical Officer | SSale | −8.22K | $12.01 | −$98.7K | −5.5%142.0K after | 10b5-1 |
| Aug 19, 2026 (view filing)9:00 PM ET | Aug 18 | 1 day | Banerjee SubhashisChief Medical Officer | SSale | −429 | $12.00 | −$5.15K | −0.3%145.0K after | 10b5-1 |
| Jul 31, 2026 (view filing)5:13 PM ET | Jul 29-31 | 2 days | RA Capital Healthcare Fund LP and 5 othersDirector, 10% Owner | PPurchase | +45.8K | $9.96 | +$455.7K | +0.3%17.3M after | 2 lots |
| Jul 28, 2026 (view filing)5:24 PM ET | Jul 24 | 4 days | RA Capital Healthcare Fund LP and 5 othersDirector, 10% Owner | PPurchase | +41.3K | $9.99 | +$412.8K | +0.2%17.3M after | |
| Jul 23, 2026 (view filing)9:22 PM ET | Jul 21-23 | 2 days | RA Capital Healthcare Fund LP and 5 othersDirector, 10% Owner | PPurchase | +264.6K | $9.76 | +$2.58M | +1.6%17.2M after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Artiva Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 17,955,642 | $174.2M | 1.51% | +8,102,340+82.2% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,604,166 | $25.3M | 0.07% | +2,604,166 | New |
| Blackstone Group Inc. | 2,403,437 | $23.3M | 0.08% | +2,403,437 | New |
| 5AM Venture Management, LLC | 2,353,304 | $22.8M | 7.93% | 00.0% | Unchanged |
| VR Adviser, LLC | 2,043,596 | $19.8M | 0.60% | +434,027+27.0% | Added |
| Franklin Resources Inc | 1,997,223 | $19.4M | 0.00% | +1,476,896+283.8% | Added |
| Caligan Partners LP | 1,736,111 | $16.8M | 0.81% | +1,736,111 | New |
| Vanguard Capital Management LLC | 981,815 | $9.52M | 0.00% | +774,129+372.7% | Added |
| Samsara BioCapital, LLC | 954,861 | $9.26M | 0.76% | +954,861 | New |
| Blue Owl Capital Holdings LP | 874,542 | $8.48M | 1.29% | +874,542 | New |